期刊文献+

Box-Behnken效应面法优化尼群地平凝胶骨架缓释片处方 被引量:2

Formulation optimization of nitrendipine gel matrix extended-release tablets by Box-behnken response surface method
下载PDF
导出
摘要 目的对尼群地平凝胶骨架缓释片的处方进行筛选和研究。方法以凝胶骨架基质HPMC K4M和HPMC100LV的用量为考察因素,药物在1、2、4、6、10h的累积释放度Y1h、Y2h、Y4h、Y6h、Y10h为考察指标,利用2因素3水平中Box-Behnken效应面法优化处方。结果联合使用HPMC K14M及HPMC 100LV作为尼群地平缓释片的基本骨架材料,乳糖作为填充剂,硬脂富马酸钠为润滑剂,85%乙醇溶液适量作为黏合剂制成尼群地平缓释骨架片在各时间点释放度符合标准。结论通过Box-Behnken效应面法优化法建立的模型可以用于尼群地平凝胶骨架缓释片处方的优化,所制得的缓释片释放度符合规定。 Objective To optimize the formulation of nitrendipine extended-release tablets.Methods Nitrendipine extended-release tablets were prepared by the mixture of hydroxypropyl methylcellulose(HPMC) K4M and HPMC 100LV as the basic matrix materials.Box-Behnken design-response surface method was applied to optimize the formulation of the nitrendipine extended-release tablets.Results The optimal formulation and technology were as follows: HPMC as the matrix material,lactose as the filler,sodium stearyl fumarate as the lubricant,and 85% ethanol as adhensive material and the accumulative release percentages at 1,2,4,6 and 10 h were consistent with the criterion.Conclusion Box-Behnken design-response surface method is suitable for optimizing the formulation of nitrendipine gel matrix extended-release tablets,complying with requirements of the ChP.
出处 《中南药学》 CAS 2013年第7期513-516,共4页 Central South Pharmacy
关键词 尼群地平 缓释片 羟丙甲纤维素 BOX-BEHNKEN效应面法 nitrendipine extended-release tablet hydroxypropyl methylcellulose Box-Behnken design-response surface method
  • 相关文献

参考文献5

  • 1Uehata A, Takase B, Nishioka T, et al. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension [J]. Am J Cardiol, 2001, 87 ( 12 ) : 1414-1416.
  • 2Brion R, Carre F, Verdier J. Comparative effects of bisoprolol and nitrendipine on exercise capacity in hypertensive patients with regular physical activity [J]. Cardiovasc Pharm, 2000, 35 ( 1 ) : 78-83.
  • 3Siddiqui A, Plosker G. Fixed dose combination enalapril and nit- rendipine: a review of its use in mild to moderate hypertension [J]. Drugs, 2004, 64 (10): 1135-1145.
  • 4宗莉,陈伶俐,张勇.尼群地平缓释片的研制及体外释药因素分析[J].中国药科大学学报,2004,35(6):503-507. 被引量:9
  • 5Lee YL, Kim MS, Park MY, et al. Quality by design: under- standing the formulation variables and optimization of metformin hydrochloride 750 mg sustained release tablet by Box-Behnken design [J]. Journal of Pharmaceutical Investigation, 2012, 42 ( 4 ): 213-220.

二级参考文献9

  • 1国家药典委员会.中华人民共和国药典(2000年版).二部临床用药须知[M].第3版.北京:化学工业出版社,2001.242.
  • 2Hasegawa GR.Drug review:nicardipine,nitrendipine and bepridil,new calcium antagonists for cardiovascular disorders[J].Clin Pharmacy,1988,7(2):97-108.
  • 3Mikus G,Eichelbaum M.Pharmacokinetics,bioavailability,metabolism and hemodynamic effects of the calcium channel antagonist nitrendipine[J].J Cardiovasc Pharmacol,1987,9(4):140-141.
  • 4Korsmeyer RW,Gurney R,Doelker E,et al.Mechanism of solute release from porous hydrophilic polymers[J].Int J Pharm,1983,15:25-35.
  • 5Ritger PL,Peppas NA.A simple equation for description of solute release Ⅰ.Fickian and non-Fickian release from non-swellable devices in the form of slabs,spheres,cylinders or discs[J].J Control Rel,1987,5(1):23-36.
  • 6Ritger PL,Peppas NA.A simple equation for description of solute release Ⅱ.Fickian and anomalous release from swellable devices[J].J Control Rel,1987,5(1):37-42.
  • 7庄阳辉,于西全.尼群地平微囊的研制及体外释放度的研究[J].海峡药学,1998,10(2):22-24. 被引量:2
  • 8朱哲英,毛凤斐,朱家璧.尼群地平缓释片剂的研究[J].中国医药工业杂志,1990,21(11):499-502. 被引量:13
  • 9杨明世,崔福德,王亮,游本刚,高鹏,范玉玲.尼群地平缓释微球的制备及其体内外相关性的研究[J].沈阳药科大学学报,2003,20(2):79-83. 被引量:9

共引文献8

同被引文献53

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部